Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort

L. Ellingwood,1 O. Schieir,2 M. F. Valois,3 S. J. Bartlett,4 L. Bessette,4 G. Boire,5 G. Hazlewood,6 C. Hitchon,7 E. C. Keystone,8 D. Tin,9 C. Thorne,9 V. P. Bykerk,10 J. E. Pope,11 and on behalf of CATCH Investigators

Background. This multicenter incident cohort aimed to characterize how often early rheumatoid arthritis (ERA) patients self-report episodic joint inflammation (palindromic rheumatism) preceding ERA diagnosis and which characteristics differentiate these patients from those without prior episodic symptoms.

Methods. Data were from patients with early confirmed or suspected RA (more than 6 weeks and less than 12 months) enrolled in the Canadian Early Arthritis CoHort (CATCH) between April 2017 to March 2018 who completed study case report forms assessing joint pain and swelling prior to ERA diagnosis. Chi-square and t tests were used to compare characteristics of patients with and without self-reported episodic joint inflammation prior to ERA diagnosis. Multivariable logistic regression was used to identify sociodemographic and clinical measures associated with past episodic joint inflammation around the time of ERA diagnosis.

Results. A total of 154 ERA patients were included; 66% were female, and mean (SD) age and RA symptom duration were 54 (15) years and 141 (118) days. Sixty-five (42%) ERA patients reported a history of episodic joint pain and swelling, half of whom reported that these symptoms preceded ERA diagnosis by over 6 months. ERA patients with past episodic joint inflammation were more often female, had higher income, were seropositive, had more comorbidities, fewer swollen joints, and lower Clinical Disease Activity Index (CDAI) around the time of ERA diagnosis (P < 0.05). These associations remained significant in multivariable regression adjusting for other sociodemographic and RA clinical measures.

Conclusion. Almost half of ERA patients experienced episodic joint inflammation prior to ERA diagnosis. These patients were more often female, had higher income, and presented with milder disease activity at ERA diagnosis.
INTRODUCTION

Palindromic rheumatism (PR) constitutes transient acute attacks of self-resolving articular and/or periarticular inflammation without radiographic damage (1–4). Although it is debated whether PR is part of the spectrum of rheumatoid arthritis (RA), estimated rates of PR progression to RA range from 50% to 67%, and PR is widely considered an at-risk phenotype for development of RA (5–7).

The prevalence of PR and how frequently it precedes RA is largely uncharacterized, and the median length of time before RA diagnosis is unknown. In one study, less than 3% of patients with musculoskeletal disorders seen by rheumatologists had PR (8). PR may be more common than previously recognized. In a Canadian retrospective study of 145 newly referred rheumatology patients, 51 were diagnosed with PR and 94 with RA, providing a relative estimate (9). Another study from the United Kingdom collected for the composite rheumatic disease comorbidity index (RDCI) and also for osteoarthritis (OA), fibromyalgia, and back or spine arthritis.

Analysis. Descriptive, chi-square, and t tests were used to compare differences in baseline characteristics in patients with versus without a reported history of PR as defined by prior transient inflammatory joint symptoms. Simple and multivariable logistic regression with backward selection ($P < 0.2$) were used to identify crude and adjusted predictors of episodic symptoms. SAS version 9.4 and SPSS version 25.0 were used.

RESULTS

Over the course of 1 year, 201 patients were recruited and 47 of those were excluded because of missing data for joint symptom questions, leaving 154 patients for analyses. Included patients had similar demographic and RA clinical characteristics as those excluded except that those excluded were less likely to be Caucasian and had more comorbidities (Supplemental Table 1).
Table 1. Baseline characteristics of ERA patients who did vs did not report transient joint episodes prior to ERA diagnosis*

| Variable                                      | Total Sample (n = 154) | ERA Patients Who Did NOT Report Prior Transient Joint Episodes (N = 89) | ERA Patients Who Reported Prior Transient Joint Episodes (N = 65) | P value |
|-----------------------------------------------|------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------|---------|
| MD-reported symptom duration (days), median (IQR) | 141 (118)              | 142 (130)                                                                | 140 (118)                                                       | 0.549   |
| Age (years), mean (SD); range                | 54 (15); 18-80         | 54 (15); 18-80                                                           | 54 (15); 22-80                                                 | 0.971   |
| Female (%)                                   | 101 (66)               | 51 (57)                                                                  | 50 (77)                                                        | 0.011   |
| Caucasian (%)                                | 124 (80)               | 73 (82)                                                                  | 51 (78)                                                        | 0.582   |
| Education (>high school) (%)                 | 84 (55)                | 46 (52)                                                                  | 38 (58)                                                        | 0.447   |
| Household income (>50,000) (%)               | 69 (59)                | 33 (52)                                                                  | 36 (68)                                                        | 0.073   |
| Smoking (%)                                  |                        |                                                                          |                                                                |         |
| Never                                         | 66 (44)                | 42 (49)                                                                  | 24 (38)                                                        | 0.167   |
| Current smoker                                | 28 (19)                | 12 (14)                                                                  | 16 (25)                                                        | 0.086   |
| Past smoker                                   | 56 (37)                | 32 (37)                                                                  | 24 (38)                                                        | 0.971   |
| Rheumatic disease comorbidity index (SD)      | 1.4 (1.5)              | 1.1 (1.3)                                                                | 1.7 (1.7)                                                      | 0.021   |
| Fibromyalgia (%)                              | 4 (3)                  | 1 (1)                                                                    | 3 (5)                                                          | 0.311   |
| Osteoarthritis (%)                            | 33 (24)                | 13 (16)                                                                  | 20 (32)                                                        | 0.017   |
| Back/spine symptoms (%)                      | 42 (29)                | 14 (17)                                                                  | 28 (45)                                                        | <0.001  |
| 2010 ACR/EULAR criteria (%)                  | 127 (83)               | 74 (83)                                                                  | 53 (82)                                                        | 0.713   |
| Seropositivity (RF or ACPA)                  | 101 (67)               | 50 (58)                                                                  | 51 (79)                                                        | 0.009   |
| RF positive (%)                               | 81 (53)                | 38 (49)                                                                  | 42 (70)                                                        | 0.012   |
| ACPA positive (%)                             | 79 (64)                | 40 (56)                                                                  | 39 (74)                                                        | 0.048   |
| Patient global assessment (SD) (0-10)         | 6 (3)                  | 5 (3)                                                                    | 6 (3)                                                          | 0.345   |
| MD global assessment (SD) (0-10)              | 5 (2)                  | 6 (2)                                                                    | 5 (3)                                                          | <0.001  |
| Tender joint count (SD) (0-28)                | 7 (5)                  | 8 (6)                                                                    | 5 (4)                                                          | 0.001   |
| CDAI (SD)                                     | 25.2 (12.5)            | 27.5 (12.4)                                                              | 22.1 (12.0)                                                    | 0.011   |
| MD-HAQ (SD)                                   | 0.9 (0.6)              | 0.8 (0.6)                                                                | 0.9 (0.6)                                                       | 0.198   |
| Oral corticosteroids (%)                      | 24 (16)                | 15 (17)                                                                  | 9 (14)                                                         | 0.611   |
| Parenteral corticosteroids (%)                | 38 (25)                | 20 (23)                                                                  | 18 (28)                                                        | 0.458   |

Bold indicate statistically significant values ($P < 0.05$).

Abbreviation: ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; ERA, early rheumatoid arthritis; EULAR, European League Against Rheumatism; IQR, intraquartile range; MD, medical doctor; MD-HAQ, Multi-Dimensional Health Assessment Questionnaire.

*Chi Square and t-test were used where appropriate.

Table 1 summarizes baseline characteristics comparing patients with and without PR prior to ERA diagnosis. Two-thirds of patients were female, mean (SD) age was 54 (15) years, and mean (SD) physician-reported symptom duration was 141 (118) days; 83 (54%) reported having previous joint pain and swelling prior to current episode; 65 (42%) endorsed prior joint pain and swelling that would “come and go,” of whom 31 (48%) reported joint symptoms that occurred more than 6 months prior to ERA diagnosis. Patients reporting PR (history episodic inflammatory joint symptoms) were more often female, seropositive, had higher average RDCI scores, and OA and back or spine arthritis. They had lower swollen joint counts, physician global assessment, and CDAI ($P < 0.05$). There were no significant differences in physician-reported RA symptom duration. Results of regression models are summarized in Tables 2 and 3. Unadjusted predictors of prior episodic inflammatory joint symptoms included female sex, higher income, seropositivity, comorbid OA, back/spine arthritis, higher RDCI, and lower swollen joint count, physician global assessment, and CDAI ($P < 0.05$).

Discussion

In this study of patients with ERA, patients frequently reported PR prior to RA. Sociodemographic and clinical measures associated with past inflammatory joint symptoms in adjusted models were female sex, higher income, seropositivity, comorbid back or spine arthritis, and lower CDAI disease activity. There were no differences in RA symptom duration between those with and without PR.

Results of the present study (20% reported PR more than 6 months prior to ERA and more than 40% within 1 year prior to diagnosis) are consistent with a previously reported rate of 23% and 50% (9, 10) but higher than two other studies (15% of 158 patients with RA had PR (12) and 5% in another study (2)).

Consistent with the reported associations with seropositivity and female sex in the present study, seropositivity has been associated with PR progression to RA (3, 13–15); in a 10-year prog-
Table 2. Univariable logistic regression examining associations between ERA baseline characteristics and history of transient joint episodes prior to ERA diagnosis

| Variable                        | Odds Ratio | 95% CI     | P Value |
|---------------------------------|------------|------------|---------|
| Age                             | 1.000      | 0.978, 1.021 | 0.971  |
| Female                          | 2.484      | 1.217, 5.070 | **0.012** |
| Caucasian                       | 0.798      | 0.358, 1.780 | 0.582  |
| Education (>high school)        | 1.316      | 0.690, 2.508 | 0.405  |
| Income (>50,000)                | 2.107      | 1.098, 4.040 | **0.025** |
| Current smoker                  | 2.095      | 0.914, 4.804 | 0.081  |
| Rheumatic disease comorbidity index | 1.303   | 1.044, 1.626 | **0.019** |
| OA                              | 2.601      | 1.174, 5.763 | **0.019** |
| Back/spine                      | 4.118      | 1.923, 8.815 | <0.001 |
| RA symptom duration             | 1.001      | 0.997, 1.005 | 0.547  |
| Seropositivity (RF or ACPA)     | 2.623      | 1.264, 5.444 | **0.010** |
| RF positive                     | 2.452      | 1.207, 4.981 | **0.013** |
| ACPA positive                   | 2.159      | 1.000, 4.663 | 0.050  |
| Patient global assessment       | 1.065      | 0.935, 1.213 | 0.343  |
| MD global assessment            | 0.771      | 0.668, 0.891 | <0.001 |
| Swollen joint count             | 0.893      | 0.830, 0.961 | 0.002  |
| Tender joint count              | 0.950      | 0.899, 1.003 | 0.065  |
| CDAI                            | 0.963      | 0.935, 0.992 | **0.014** |
| MD-HAQ                          | 1.495      | 0.811, 2.757 | 0.197  |

Bold indicate stat significant values (P < 0.05).

Abbreviation: ACPA, anticitrullinated protein antibodies; CDAI, Clinical Disease Activity Index; CI, confidence interval; ERA, early rheumatoid arthritis; MD, medical doctor; MD-HAQ, Multi-Dimensional Health Assessment Questionnaire; OA, osteoarthritis; RF, rheumatoid factor.

Diagnostic study of PR, female patients with positive RF and hand involvement had an 8-fold risk of developing connective tissue disease relative to patients with one or fewer of these traits (8). Seropositive RA is also associated with progression to more erosive and severe disease (16–19); thus, early clinical recognition of this patient group has important prognostic implications.

Patients with prior episodic inflammatory joint symptoms also had more comorbidities with higher RDCl comorbidity counts, more frequent OA, and self-reported back or spine arthritis. Although cervical spine involvement is thought to be rare at onset of RA, it may be an early manifestation of RA and has been reported as a presenting symptom (20). Moreover, the presence of a concomitant musculoskeletal condition such as OA or fibromyalgia has previously been identified as the most significant predictor of prolonged time from RA symptom onset to treatment (21). A larger sample size is required to further assess the likely association of OA and RDCl with palindromic symptoms.

Additionally, makers of disease activity were lower in this subset of patients, suggesting a possible insidious onset or milder disease activity at RA diagnosis, including lower swollen joint count, physician global assessment, and CDAI. In another Canadian cohort study comparing PR patients with new RA patients, inflammatory markers were generally higher in new-onset RA but were often also elevated in PR (9). Our findings suggest that patients with self-reported transient symptoms have relatively lower disease activity at study enrollment. In clinical practice, the finding that ERA patients frequently experience transient initial joint symptoms can help inform early recognition of disease, which initially may be more insidious or milder in this patient group.

Few studies have quantified patient symptoms preceding ERA diagnosis (22,23) or characterized PR preceding ERA (5–7). The strengths of this study are its unique quantitative characterization of episodic inflammatory symptoms prior to ERA and inclusion of ERA patients from multiple centers. A limitation of this study is the exclusion of 47 patients for missing data for joint symptom questions. Another limitation is that previous joint pain and swelling was reported by patients rather than physician-verified episodes of inflammatory arthritis; we are thus unable to verify whether patient-reported symptoms constituted inflammatory arthritis, previous PR, or may be attributable to comorbid musculoskeletal conditions such as OA. Our findings suggest that half of the patients with early onset RA had an episodic prodrome of inflammatory arthritis symptoms before the onset of RA.

As defined by Pasero and Barbieri (2), PR involves more than five recurrent attacks over 2 years of sudden onset monarthritis, with physician verification of one attack; negative radiographs, RF, and inflammatory markers; attacks in three or more different joints; and exclusion of other arthropitides. Hannonen et al expanded their definition to include mono- or polyarthritis and periarticular tissue inflammation lasting anywhere from a few hours to 1 week and excluded radiographic and serologic criteria (3); similar criteria were proposed by Guerne and Weisman (4), including a 6-month history of these brief symptoms and no radiographic damage. Diagnostic criteria for

Table 3. Multivariable logistic regression examining associations between ERA baseline characteristics and history of transient joint episodes prior to ERA diagnosis

| Variable                        | OR       | 95% CI     |
|---------------------------------|----------|------------|
| Age (years)                     | 0.997    | 0.966, 1.029 |
| Female                          | 3.305    | **1.165, 9.366** |
| Household income (>50,000)      | 2.539    | **1.063, 6.063** |
| Rheumatic disease comorbidity index | 1.347   | 0.994, 1.825 |
| Osteoarthritis                  | 3.102    | 0.996, 9.658 |
| Back/spine symptoms             | 2.974    | **1.145, 7.723** |
| Seropositivity                  | 3.641    | 1.343, 9.873 |
| CDAI                            | 0.949    | 0.912, 0.988 |

Bold indicate stat significant values (P < 0.05).

Abbreviation: CDAI, Clinical Disease Activity Index; CI, confidence interval; ERA, early rheumatoid arthritis; MD, medical doctor; OR, odds ratio.

*Non-significant variables: current smoker, MD global assessment. Twenty-one patients were excluded from multivariate analysis because of missing data.
PR were not included in the current study of patient-reported transient symptoms of joint pain and swelling that would come and go. Despite this, there are differences for patients with episodic symptoms by self-report such as more seropositivity. Further research is required to characterize physician-diagnosed PR and its relationship with RA onset.

Recently, cases of RA have been described with overlapping autoimmune and autoinflammatory clinical phenotypes characterized by abrupt inflammatory attacks with fever, joint swelling, erythema, and elevated inflammatory markers (24). Our finding that patient-reported episodic inflammatory joint symptoms are prevalent amongst patients with ERA further highlights the importance of characterizing the phenotypic variability of ERA.

Patients with ERA frequently reported experiencing transient episodes of inflammatory arthritis prior to RA diagnosis. ERA patients who endorsed a history of joint symptoms that come and go prior to RA diagnosis were more likely female and seropositive with higher income and lower CDAI at ERA cohort entry, but median ERA duration did not differ. These findings have implications for earlier RA recognition in routine clinical practice, particularly for patients with more insidious or milder disease activity at RA onset.

ACKNOWLEDGMENTS

The authors thank the CATCH investigators: Murray Baron, Louis Bessette, Gilles Boire, Vivian Bykerk, Ines Colmegna, Sabrina Fallavollita, Derek Haaland, Paul Haraoui, Glen Hazlewood, Carol Hitchon, Shahin Jamal, Raman Joshi, Ed Keystone, Bindu Nair, Peter Panopoulos, Janet Pope, Laurence Rubin, Carter Thorne, Edith Villeneuve, Michel Zummer.

AUTHOR CONTRIBUTIONS

L. Ellingwood, O. Schier, M.F. Valois, S.J. Bartlett, L. Bessette, G. Boire, G. Hazlewood, C. Hitchon, E.C. Keystone, D. Tin, C. Thorne, V.P. Bykerk, and J.E. Pope have made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data. All authors have been involved in drafting the work or revising it critically for important intellectual content and have provided final approval of the version submitted. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Study conception and design. Ellingwood, Schier, Bykerk, Pope.

Acquisition of data. Bessette, Boire, Hitchon, Keystone, Tin, Thorne, Bykerk, Pope.

Analysis and interpretation of data. Ellingwood, Schier, Valois, Bartlett, Bessette, Boire, Hazlewood, Hitchon, Keystone, Tin, Thorne, Bykerk, Pope.

REFERENCES

1. Hench JJ, Rosenberg EF. Palindromic rheumatism. Arch Intern Med 1944;73:293–321.

2. Pasero G, Barbieri P. Palindromic rheumatism: you just have to think about it! [X]. Clin Exp Rheumatol 1986;4:197–9.

3. Hannonen P, Möttönen T, Oka M. Palindromic rheumatism. A clinical survey of sixty patients. Scand J Rheumatol 1987;16:413–20.

4. Guerne PA, Weisman MH. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am J Med 1992;93:451–60.

5. Emad Y, Anbar A, Abo-Elyoun I, El-Shaarawy N, Al-Hannaf H, Darwish H, et al. In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up. Clin Rheumatol 2014;33:791–7.

6. Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: long-term outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009;36:1873–5.

7. Mankia K, Emery P. What can palindromic rheumatism tell us? [review]. Best Pract Res Clin Rheumatol 2017;31:90–8.

8. Gonzalez-Lopez L, Gamez-Nava JJ, Jiangri GS, Ramos-Remus C, Russell AS, Suarez-Almazor ME. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. J Rheumatol 1999;26:540–5.

9. Powell A, Davis P, Jones N, Russell AS. Palindromic rheumatism is a common disease: comparison of new-onset palindromic rheumatism compared to new-onset rheumatoid arthritis in a 2-year cohort of patients. J Rheumatol 2008;35:992–4.

10. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973;2:96–100.

11. McKeown E, Bykerk VP, De Leon F, Thorne JC, Hitchon CA, Boire G, Haraoui B, Ferland DS, Keystone EC, Pope JE, on behalf of CATCH Investigators. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 2012. https://doi.org/10.1093/rheumatology/kes079.

12. Corominas H, Nava J, Díaz-Torre C, Salvador G, Gomez-Cabalero ME, de la Fuente D, et al. Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia: the AUDIT Study. Rheumatol Clin 2016;12:146–50.

13. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006;33:1240–2.

14. Tanai M, Kawakami A, Iwamoto N, Arima K, Aoyagi K, Eguchi K. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. Scand J Rheumatol 2010;39:287–91.

15. Sanmartí R, Cabrera-Villalba S, Gómez-Puerta JA, Ruiz-Esquivé E, Hernández MV, Salvador G, et al. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study. J Rheumatol 2012;39:1929–33.

16. Berglin E, Johansson S, Sundin U, Jidell U, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453–8.

17. Machold KP, Stamm TA, Eberl GJ, Noll VR, Dunkey A, Uffmann M, et al. Very recent onset arthritis–clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002;29:2278–87.

18. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.

19. Taylor P, Garthemann J, Hsieh J, Creedon J. A systemic review of serum biomarkers of anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011;8:15038.
20. Del Grande M, Del Grande F, Carrino J, Bingham CO III, Louie GH. Cervical spine involvement early in the course of rheumatoid arthritis. Semin Arthritis Rheum 2014;43:738–44.
21. Tavares R, Pope JE, Trembay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. J Rheumatol 2012;39:2088–97.
22. Peerboom D, Van der Elst K, De Cock D, Stouten V, Meyfroidt S, Joly J, et al. FRI0354 The patient trajectory from symptom onset until referral to a rheumatologist. Ann Rheum Dis 2015;74:554.
23. Raciborski F, Klak A, Kwiatkowska B, Batko B, Sochocka-Bykowska M, Zor-–Giebel A, et al. Diagnostic delays in rheumatic diseases with associated arthritis. Reumatologia 2017;55:169–76.
24. Savic S, Mistry A, Wilson AG, Barcenas-Morales G, Doffinger R, Emery P, et al. Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. RMD Open 2017;3:e000550.

APPENDIX A: CATCH INVESTIGATORS

Murray Baron, Louis Bessette, Gilles Boire, Vivian Bykerk, Ines Colmegna, Sabrina Fallavollita, Derek Haaland, Paul Haraoui, Glen Hazlewood, Carol Hitchon, Shahin Jamal, Raman Joshi, Ed Keystone, Bindu Nair, Peter Panopoulos, Janet Pope, Laurence Rubin, Carter Thorne, Edith Villeneuve, Michel Zummer.